1. Home
  2. GKOS vs OCFCP Comparison

GKOS vs OCFCP Comparison

Compare GKOS & OCFCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • OCFCP
  • Stock Information
  • Founded
  • GKOS 1998
  • OCFCP N/A
  • Country
  • GKOS United States
  • OCFCP United States
  • Employees
  • GKOS N/A
  • OCFCP 1007
  • Industry
  • GKOS Medical/Dental Instruments
  • OCFCP Major Banks
  • Sector
  • GKOS Health Care
  • OCFCP Finance
  • Exchange
  • GKOS Nasdaq
  • OCFCP Nasdaq
  • Market Cap
  • GKOS 5.1B
  • OCFCP N/A
  • IPO Year
  • GKOS 2015
  • OCFCP N/A
  • Fundamental
  • Price
  • GKOS $95.76
  • OCFCP $25.35
  • Analyst Decision
  • GKOS Strong Buy
  • OCFCP
  • Analyst Count
  • GKOS 13
  • OCFCP 0
  • Target Price
  • GKOS $155.00
  • OCFCP N/A
  • AVG Volume (30 Days)
  • GKOS 981.4K
  • OCFCP N/A
  • Earning Date
  • GKOS 04-30-2025
  • OCFCP N/A
  • Dividend Yield
  • GKOS N/A
  • OCFCP N/A
  • EPS Growth
  • GKOS N/A
  • OCFCP N/A
  • EPS
  • GKOS N/A
  • OCFCP N/A
  • Revenue
  • GKOS $383,481,000.00
  • OCFCP N/A
  • Revenue This Year
  • GKOS $27.84
  • OCFCP N/A
  • Revenue Next Year
  • GKOS $27.99
  • OCFCP N/A
  • P/E Ratio
  • GKOS N/A
  • OCFCP N/A
  • Revenue Growth
  • GKOS 21.85
  • OCFCP N/A
  • 52 Week Low
  • GKOS $77.91
  • OCFCP N/A
  • 52 Week High
  • GKOS $163.71
  • OCFCP N/A
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 50.65
  • OCFCP 60.16
  • Support Level
  • GKOS $87.17
  • OCFCP $25.24
  • Resistance Level
  • GKOS $94.55
  • OCFCP $25.36
  • Average True Range (ATR)
  • GKOS 6.20
  • OCFCP 0.04
  • MACD
  • GKOS 1.57
  • OCFCP 0.00
  • Stochastic Oscillator
  • GKOS 94.20
  • OCFCP 93.06

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About OCFCP OceanFirst Financial Corp. Depositary Shares

OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.

Share on Social Networks: